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Glossary
Absorption-The transport of a chemical from the outer surface of the skin into both the skin and systemic circulation (including penetration, permeation, and resorption).
Acute exposure-Contact with a chemical that occurs once or for only a short period of time.
Cancer-Any one of a group of diseases that occurs when cells in the body become abnormal and grow or multiply out of control.
Contaminant-A chemical that is (1) unintentionally present within a neat substance or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen and present within a neat substance or mixture at a concentration less than 0.1%.
Cutaneous (or percutaneous)-Referring to the skin (or through the skin).
Dermal-Referring to the skin.
Dermal contact-Contact with (touching) the skin.
Direct effects-Localized, non-immune-mediated adverse health effects on the skin, including corrosion, primary irritation, changes in skin pigmentation, and reduction/disruption of the skin barrier integrity, occurring at or near the point of contact with chemicals.
Immune-mediated responses-Responses mediated by the immune system, including allergic responses.
Sensitization-A specific immune-mediated response that develops following exposure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis (ACD) or other immune-mediated diseases such as asthma, depending on the site and route of re-exposure.
Substance-A chemical.
Systemic effects-Systemic toxicity associated with skin absorption of chemicals after exposure of the skin. 
Purpose
This skin notation profile presents (1) a brief summary of epidemiological and toxicological data associated with skin contact with arsenic and (2) the rationale behind the hazard-specific skin notation (SK) assignment for arsenic. The SK assignment is based on the scientific rationale and logic outlined in the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009 ]. The summarized information and health hazard assessment are limited to an evaluation of the potential health effects of dermal exposure to arsenic. A literature search was conducted through February 2013 to identify information on arsenic, including but not limited to data relating to its toxicokinetics, acute toxicity, repeated-dose systemic toxicity, carcinogenicity, biological system/function-specific effects (including reproductive and developmental effects and immunotoxicity), irritation, and sensitization. Information was considered from studies of humans, animals, or appropriate modeling systems that are relevant to assessing the effects of dermal exposure to arsenic.
Overview of SK Assignment
Arsenic is potentially capable of causing skin irritation following skin contact. A critical review of available data has resulted in the following SK assignment for arsenic: SK: DIR (IRR). Table 1 provides an overview of the critical effects and data used to develop the SK assignment for arsenic. 
Systemic Toxicity from Skin Exposure (SK: SYS)
Toxicokinetic studies following dermal exposure to arsenic and its inorganic compounds were identified. Although no in vivo studies in humans were identified, in vivo toxicokinetic studies in monkeys and rats demonstrate that arsenic is absorbed following dermal exposure. Wester et al. [1993] reported that 6.4% and 2.0% of the applied arsenic dose were absorbed through the skin when radioactive water solutions of arsenic-73 as arsenic acid at a low (trace) level of 0.000024 micrograms per square centimeter (μg/cm 2 ), and a higher dose of 2.1 μg/cm 2 , respectively, were applied in a volume of 5 microliters (μL)/cm 2 to the skin of Rhesus monkey for 24 hours. In rats, skin application of sodium arsenate aqueous solutions for one hour caused the initial accumulation of arsenic in the skin, with the absorption rate of 1.14-33.1 g/cm 2 -hour for 0.01 to 0.2 molar (M) concentrations, followed by a slow and continuous distribution to the blood stream and to other tissues [Dutkiewicz 1977] . Thirty percent of the absorbed dose was eliminated in the urine and feces at 10 days after the skin application. Dutkiewicz [1977] calculated that this absorption rate would result in an overall absorption rate of 0.8 to 23.2 milligrams (mg)/hour in humans, assuming the surface area of the hands to be 700 cm 2 . Wester et al. [1993] reported a percutaneous absorption of 1.9% of the applied dose (when receptor fluid and skin concentrations were added) when the low level radioactive water solution of arsenic-73 of 0.000024 μg/cm 2 , as used in the Rhesus monkey study, was applied to human skin in vitro for 24 hours. The value from the in vitro study was less than the in vivo percutaneous absorption of 6.4% in the Rhesus monkey. When arsenic-73 was applied to 0.64 cm 2 dermatosed pig skin samples for 16 hours, Turkall [2003] reported total penetration (sum of the radioactivity of the initial dose in the receptor fluid of 0.4% and the remaining dose of 44.2% bound to skin) as 44.6% of the initial dose recovered at the end of the 16-hour study. This study indicated that more arsenic bound to the skin following topical application than penetrated into receptor fluid. The potential of arsenic to pose a skin absorption hazard was not evaluated with a predictive algorithm for estimating and evaluating the health hazards of dermal exposure to substances [NIOSH 2009 ]. The evaluation method compares an estimated dose accumulated in the body from skin absorption and an estimated dose from respiratory absorption associated with a reference occupational exposure limit (OEL). The ratio of the skin dose to the inhalation dose (SI ratio) could not be calculated because this method is not validated to determine skin absorption for inorganic compounds. More information about the SI ratio can be found in the appendix. Wester et al. [1993] demonstrated that the presence of other chemicals significantly enhanced the dermal bioavailability of arsenic. The partition coefficient (k p ) of arsenic chloride from water to powdered human stratum corneum was reported as 1.1 x 10 4 [Wester et al. 1993] . It is important to note that lead arsenate compounds have low solubility in water [Liu et al. 2009 ], and would not be as hazardous as some of the other inorganic compounds of arsenic described in this document. Based on the available toxicokinetic studies in both humans and animals, arsenic has limited potential to be absorbed through human skin compared to animal skin.
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No estimated dermal lethal doses (LD Lo ) of arsenic for humans have been identified. However, a dermal LD 50 (the dose resulting in 50% mortality in the exposed animals) value of greater than 2,400 milligrams per kilogram body weight (mg/kg) was reported for female rats for arsenic as lead or calcium arsenate [Gaines 1960 ]. Because the reported acute dermal LD 50 value for the rat is greater than the critical dermal LD 50 value of 2000 mg/kg that identifies chemical substances with the potential for acute dermal toxicity [NIOSH 2009 ], arsenic and its inorganic compounds are not considered acutely toxicity following dermal exposure.
No epidemiological or occupational exposure studies or repeat-dose, sub-chronic or chronic toxicity studies in animals were identified that evaluated system effects following dermal exposure to arsenic or its inorganic compounds. No specialty studies were identified that evaluated biological system/function specific effects (including reproductive effects and immunotoxicity) following dermal exposure to arsenic. A case report by Robinson [1975] described peripheral neuropathy in a man who was dermally treated with arsenic; however detailed information was not provided.
No studies that evaluated the carcinogenic potential of arsenic or its inorganic compounds following the dermal exposure route were identified. The classification of carcinogenicity of arsenic following dermal exposure has not been done, but several organizations have developed such classifications based on data from other exposure routes. It should be noted that skin cancers in the form of Bowen's disease, a squamous cell carcinoma in situ, and basal cell carcinomas, are commonly associated with the chronic ingestion and inhalation of arsenic [ATSDR 2007] . The relationship between skin contact with arseniccontaining compounds and these diseases could not be determined because of the absence of quality data on the subject. Table 2 summarizes carcinogenic designations of multiple governmental and nongovernmental organizations for arsenic. There is some indication from toxicokinetic studies that arsenic has measurable but limited potential to be absorbed through the skin of humans and animals [Dutkiewicz 1977; Wester et al. 1993; Turkall 2003 ]. The limited availability by the dermal route is consistent with the results of the acute dermal toxicity study identified in animals [Gaines 1960 ] that indicates that arsenic is not acutely toxic despite its known acute toxicity via other routes. In addition, the lack of case reports, epidemiological studies, prolonged or repeat-dose studies in animals precludes adequate evaluation of the potential of arsenic to cause systemic effects following dermal exposure. Therefore, on the basis of the data for this assessment, arsenic is not assigned the SK: SYS notation.
Direct Effects on Skin (SK: DIR)
No human or animal in vivo studies on corrosivity of arsenic or in vitro tests for corrosivity using human or animal skin models or in vitro tests of skin integrity using cadaver skin were identified. However, several occupational cases or human studies have reported irritant contact dermatitis or cutaneous effects in patients or workers exposed to arsenic [Pinto and McGill 1953; Bourrain 1998; Mohamed 1998 ]. Skin reactions were mostly in the form of itching, dryness, hyperpigmentation, folliculitis, superficial ulceration, erythema, swelling, and papules, with vesicle formation in severe cases. In mice treated twice daily with 50 μL of 0.4% potassium arsenite solution in 80% ethanol extensive ulceration was observed [Boutwell 1963 ]. Boutwell [1963] evaluated the tumor initiation and promotion potential of topical applications of potassium arsenite in ethanol. In an 18-week initiation study, mice received a total of 1.24 mg of potassium arsenite divided into 8 applications over 5 days. The tumor-promoting agent, croton oil (25 μL of 2.0% concentration in benzene) was then applied twice weekly to the skin beginning 2 days after application of the test material. No increase in tumorigenicity was observed [Boutwell 1963 ]. In a 30-week tumor-promotion study, 20 mice were given a single application of 75 μg of 7,12-dimethylbenz(a)anthracene (DMBA) in 25 μL of acetone to a shaved area on the skin, followed by twice daily (11 times a week) application with 50 μL of 0.4% potassium arsenite solution in 80% ethanol. The exposure resulted in a weekly cumulative dose of 2.2 mg potassium arsenite [Boutwell 1963 ]. Although hyperplasia and external ulceration were observed, no tumors were identified. Boutwell [1963] concluded potassium arsenite was neither a tumor initiator nor promoter.
Case reports and human studies [Pinto and McGill 1953; Bourrain 1998; Mohamed 1998] 2
demonstrate that chronic or high-dose dermal exposure to arsenic can result in irritant contact dermatitis. Some of the irritant symptoms observed could possibly reflect other ingredients. Moreover, some of the observed skin effects could arise from arsenic uptake via other routes of exposure (e.g., oral, inhalation) in the occupational setting. However, the effects are consistent with irritation and are supported by the finding that prolonged exposure to arsenic following dermal application resulted in extensive ulceration at the site of application in mice [Boutwell 1963 ]. Therefore, on the basis of the data for this assessment, arsenic is assigned the SK: DIR (IRR) notation. Several studies were identified that evaluated the potential of arsenic to cause skin sensitization in humans and animals. Wahlberg and Boman [1986] reported two out of 379 (0.5%) eczema patients patch tested with arsenic compounds [0.1% sodium arsenate in distilled water (pH 8.5) and 0.05% sodium arsenite in distilled water (pH 10.0)] that showed positive test results. The patients had no known previous exposure to arsenic compounds and the positive response might have been due to a cross reactivity with nickel. In a guinea pig maximization test (GPMT), arsenic compounds (1.0% sodium arsenate and 0.1% sodium arsenite) were not sensitizing to the skin, and were not rated as Grade I Allergens [Wahlberg and Boman 1986 ].
An in vivo animal study using the GPMT did not support the weak skin sensitization data in humans [Wahlberg and Boman 1986] . This assessment concludes that data are too limited to conclude that arsenic and its inorganic compounds have the potential to cause skin sensitization in humans. Therefore, on the basis of the data for this assessment, arsenic is not assigned the SK: SEN notation.
Summary
There is some indication from toxicokinetic studies that arsenic and its inorganic compounds have measurable, but limited potential to be absorbed through the skin of humans and animals [Dutkiewicz 1977; Wester et al. 1993; Turkall 2003 ]. The limited availability by the dermal route is consistent with the results of the acute dermal toxicity study identified in animals [Gaines 1960 ] that indicates that arsenic is not acutely toxic despite its known acute toxicity via other routes. These data are insufficient to adequately evaluate the potential of arsenic and its inorganic compounds to cause systemic effects, including skin cancers, following dermal exposure. Case reports and human studies [Pinto and McGill 1953; Bourrain 1998; Mohamed 1998 ] and data from animals [Boutwell 1963 ] indicate that chronic or high-dose dermal exposure to arsenic can result in irritant contact dermatitis. An in vivo animal study using the GPMT did not support the weak skin sensitization data in humans [ Wahlberg and Boman 1986] . Therefore, on the basis of these assessments, arsenic is assigned a composite skin notation of SK: DIR (IRR). 
Appendix: Calculation of the SI Ratio
This appendix presents an overview of the SI ratio. Although the SI ratio is considered in the determination of a substance's hazard potential following skin contact, it is intended only to serve as supportive data during the assignment of the NIOSH SK. An in-depth discussion on the rationale and calculation of the SI ratio can be found in Appendix B of the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009 ].
Overview
The SI ratio is a predictive algorithm for estimating and evaluating the health hazards of skin exposure to substances. The algorithm is designed to evaluate the potential for a substance to penetrate the skin and induce systemic toxicity [NIOSH 2009 ]. The goals for incorporating this algorithm into the proposed strategy for assigning SYS notation are as follows:
(1) Provide an alternative method to evaluate substances for which no clinical reports or animal toxicity studies exist or for which empirical data are insufficient to determine systemic effects. (2) Use the algorithm evaluation results to determine whether a substance poses a skin absorption hazard and should be labeled with the SYS notation.
The algorithm evaluation includes three steps:
(1) determining a skin permeation coefficient (k p ) for the substance of interest, (2) estimating substance uptake by the skin and respiratory absorption routes, and (3) evaluating whether the substance poses a skin exposure hazard.
The algorithm is flexible in the data requirement and can operate entirely on the basis of the physicochemical properties of a substance and the relevant exposure parameters. Thus, the algorithm is independent of the need for biologic data. Alternatively, it can function with both the physicochemical properties and the experimentally determined permeation coefficient when such data are available and appropriate for use.
The first step in the evaluation is to determine the k p for the substance to describe the transdermal penetration rate of the substance [NIOSH 2009 ]. The k p , which represents the overall diffusion of the substance through the stratum corneum and into the blood capillaries of the dermis, is estimated from the compound's molecular weight (MW) and base-10 logarithm of its octanol-water partition coefficient (log KOW). In this example, k p is determined for a substance with use of Equation 1. A self-consistent set of units must be used, such as outlined in Table A1 . Other model-based estimates of k p may also be used [NIOSH 2009 ].
